De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
HIMS Overzicht aandelen
Hims & Hers Health, Inc. exploiteert een telegezondheidsplatform dat consumenten verbindt met bevoegde zorgverleners in de Verenigde Staten, het Verenigd Koninkrijk en internationaal.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Expanding Into Personalized Weight Management And AI Integration Spurs Market Leadership
Hims & Hers are taking grip on Telemedicine
Hims & Hers Health, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$17.66 |
| 52 Week Hoogtepunt | US$25.74 |
| 52 Week Laag | US$5.65 |
| Bèta | 1.06 |
| 11 maand verandering | 29.38% |
| 3 maanden verandering | -14.64% |
| 1 Jaar Verandering | 179.87% |
| 33 jaar verandering | 136.10% |
| 5 jaar verandering | 79.75% |
| Verandering sinds IPO | 80.20% |
Recent nieuws en updates
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Recent updates
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Rendement voor aandeelhouders
| HIMS | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -4.1% | -1.2% | 0.1% |
| 1Y | 179.9% | 8.2% | 32.2% |
Rendement versus industrie: HIMS overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 10.8 % opleverde.
Rendement versus markt: HIMS overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.
Prijsvolatiliteit
| HIMS volatility | |
|---|---|
| HIMS Average Weekly Movement | 9.3% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: HIMS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van HIMS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 1,046 | Andrew Dudum | www.forhims.com |
Hims & Hers Health, Inc. exploiteert een telegezondheidsplatform dat consumenten in contact brengt met bevoegde zorgverleners in de Verenigde Staten, het Verenigd Koninkrijk en internationaal. Het bedrijf biedt een scala aan gezondheids- en welzijnsproducten en -diensten op recept en zonder recept die klanten rechtstreeks kunnen kopen op haar websites en mobiele applicatie. Het bedrijf biedt ook medicijnen op recept op terugkerende basis en voortdurende zorg van zorgverleners; en receptvrije geneesmiddelen en hulpmiddelen, cosmetica en supplementen, voornamelijk gericht op algemeen welzijn, seksuele gezondheid en welzijn, huidverzorging en haarverzorging.
Hims & Hers Health, Inc. Samenvatting
| HIMS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$3.82b |
| Inkomsten(TTM) | US$18.10m |
| Inkomsten(TTM) | US$1.07b |
211.1x
Koers/Winstverhouding3.6x
P/S-verhoudingIs HIMS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HIMS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.07b |
| Kosten van inkomsten | US$190.06m |
| Brutowinst | US$877.07m |
| Overige uitgaven | US$858.97m |
| Inkomsten | US$18.10m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.084 |
| Brutomarge | 82.19% |
| Nettowinstmarge | 1.70% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde HIMS op de lange termijn?
Bekijk historische prestaties en vergelijking